Co-Authors
This is a "connection" page, showing publications co-authored by Wendy Stock and Anand Patel.
Connection Strength
4.390
-
Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021 Aug; 2(3):413-420.
Score: 0.717
-
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57.
Score: 0.666
-
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
Score: 0.242
-
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis. Blood Cancer J. 2025 Oct 06; 15(1):158.
Score: 0.241
-
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
Score: 0.236
-
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem. 2025 Feb; 6(1):e1076.
Score: 0.229
-
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia. Blood Adv. 2024 09 10; 8(17):4647-4650.
Score: 0.224
-
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
Score: 0.219
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
Score: 0.216
-
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
Score: 0.213
-
Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
Score: 0.208
-
Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.
Score: 0.196
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.166
-
Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials. Blood. 2026 Feb 05; 147(6):639-649.
Score: 0.062
-
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors. Haematologica. 2026 Jan 29.
Score: 0.062
-
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia. Haematologica. 2026 Jan 15.
Score: 0.062
-
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
Score: 0.060
-
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 11 26; 8(22):5735-5743.
Score: 0.057
-
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
Score: 0.057
-
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
Score: 0.053
-
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 11; 623(7989):1034-1043.
Score: 0.053
-
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505.
Score: 0.053
-
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
Score: 0.052
-
Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. Blood. 2022 04 07; 139(14):2212-2226.
Score: 0.047